以白细胞介素1β为靶点治疗动脉粥样硬化研究进展

Research Progress of Treatment of Atherosclerosis by Targeting Interleukin-1β

近来的研究表明动脉粥样硬化本质上是一种血管的慢性炎症反应性疾病,白细胞介素1β在其发展过程中起到关键性调节作用。血管内各种因素导致的内皮细胞损伤可导致白细胞介素1β的大量表达,通过与白细胞介素1Ⅰ型受体结合并激活NF-κB信号通路,诱导二级炎性调节物白细胞介素6、肿瘤坏死因子α等大量生成。动物实验及临床实验结果表明拮抗白细胞介素1β信号通路有利于改善心肌重构,降低动脉粥样硬化所致心血管事件发病风险,以白细胞介素1β为靶点治疗动脉粥样硬化具有良好的临床应用前景。

Recent studies have shown that atherosclerosis is essentially a chronic vascular inflammatory disease,in which interleukin-1β plays a key regulatory role. Vascular endothelial cell damage caused by a variety of factors can lead to overexpression of interleukin-1β. By combination with interleukin-1 I receptor and activating NF-κB signaling pathway,interleukin-1β induces the synthesis of a large number of secondary inflammatory mediators,such as IL-6,TNFα. The results of animal experiment and clinical trials showed that antagonizing interleukin-1β signaling pathway was conducive to improving cardiac remodeling and reducing the risk of atherosclerotic cardiovascular events. The treatment of atherosclerosis targeting interleukin-1β has promising prospects for clinical application.